The promise and challenges of immune agonist antibody development in cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune cell function is modulated by co-inhibitory and co-stimulatory receptors.
• Current cancer immunotherapies primarily utilize antagonist antibodies to block negative immune checkpoints like PD1 and CTLA4.
• Agonist antibodies targeting co-stimulatory receptors represent a promising next generation of cancer therapeutics.

Purpose of the Study:

• To review the design and development considerations for immune agonist antibodies.
• To differentiate agonist antibodies from antagonist antibodies in cancer immunotherapy.
• To outline the current landscape of agonist antibodies in clinical development for cancer treatment.

Main Methods:

• Literature review of preclinical and clinical studies on immune agonist antibodies.
• Analysis of antibody design principles for co-stimulatory receptor targeting.
• Comparative assessment of agonist versus antagonist antibody mechanisms.

Main Results:

• Agonist antibodies offer a distinct therapeutic approach by activating immune responses, unlike antagonists that block inhibitory signals.
• Key considerations in agonist antibody development include target selection, efficacy, and potential toxicities.
• A growing number of agonist antibodies are progressing through clinical trials for various cancers.

Conclusions:

• Immune agonist antibodies hold significant promise for advancing cancer immunotherapy.
• Careful design and development are crucial to overcome potential challenges and harness the full therapeutic potential of agonist antibodies.
• The clinical landscape of agonist antibodies is rapidly expanding, offering new hope for cancer patients.